{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:39:40Z","timestamp":1789011580604,"version":"build-2803163510"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016114","name":"Zhejiang Medical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the efficacy and safety of intermittent, oral famciclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We retrospectively analyzed the incidence of bortezomib treatment-related varicella-zoster virus reactivation in 719 newly-diagnosed multiple myeloma patients receiving intermittent oral famciclovir prophylaxis, continuous oral acyclovir prophylaxis or no prophylaxis. The definition of intermittent oral famciclovir prophylaxis was oral famciclovir at a dose of 250mg twice daily for 9 days after finishing the last dose of bortezomib therapy every cycle. Age, gender, stage per the International Staging System, type of M protein, baseline of absolute lymphocyte count, absolute neutrophil count, and absolute monocyte count were analyzed to find the potential factors that could predispose to herpes zoster infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Varicella-zoster virus infection occurred in 96 patients (13.4%) during bortezomib treatment. The incidence of herpes zoster was significantly higher in the non-prophylaxis group compared with the prophylaxis group (22.9% vs 8.2% P&amp;lt;0.001), while the rate was similar between the intermittent oral famciclovir group and the continuous oral acyclovir group (8.4% vs 7.9% P=0.835). Hepatic and renal toxicity were observed in 12% and 2.8% of the patient respectively in the intermittent famciclovir group, which was similar in the continuous acyclovir group (18.1% and 4.2%). The prophylactic use of antiviral agents is a predictive factor for varicella-zoster virus reactivation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Intermittent famciclovir prophylaxis is effective and safe in preventing herpes zoster development and can markedly reduce the duration of oral medicine treatment compared with continuous acyclovir prophylaxis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.843032","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T07:17:58Z","timestamp":1646983078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Gaofeng","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangshu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20838","article-title":"The High Incidence of Varicella Herpes Zoster With the Use of Bortezomib in 10 Patients","volume":"82","author":"Tong","year":"2007","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5045\/kjh.2010.45.3.188","article-title":"The Risk Factors for Herpes Zoster in Bortezomib Treatment in Patients With Multiple Myeloma","volume":"45","author":"Yi","year":"2010","journal-title":"Korean J Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016","volume":"14","author":"Anderson","year":"2016","journal-title":"J Natl Compr Cancer Network Jnccn"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to Prevent Reactivation of Varicella Zoster Virus (Herpes Zoster) in Multiple Myeloma Patients Receiving Bortezomib Therapy","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.036","article-title":"Varicella-Zoster Virus Prophylaxis With Low-Dose Acyclovir in Patients With Multiple Myeloma Treated With Bortezomib","volume":"9","author":"Pour","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1078155209350374","article-title":"Prophylactic Antivirals may be Helpful in Prevention of Varicella-Zoster Virus Reactivation in Myeloma, But are They Safe","volume":"16","author":"Dasanu","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of Treatment-Emergent Peripheral Neuropathy in Multiple Myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia: Off J Leukemia Soc America Leukemia Res Fund U.K"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000913","article-title":"Famciclovir for Treatment of Herpesvirus Infections","volume":"30","author":"Luber","year":"1996","journal-title":"Ann Pharmacotherapy"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma: Results of a Multicenter Phase 1\/2 Study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.09.008","article-title":"Daily 500 Mg Valacyclovir Is Effective for Prevention of Varicella Zoster Virus Reactivation in Patients With Multiple Myeloma Treated With Bortezomib","volume":"32","author":"Fukushima","year":"2012","journal-title":"Anticancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq194","article-title":"Low-Dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated With Bortezomib: A Report From the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study","volume":"41","author":"Kim","year":"2010","journal-title":"Japanese J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09233.x","article-title":"Low-Dose Acyclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients","volume":"159","author":"Minarik","year":"2012","journal-title":"Br J Haematology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1007-3969.2014.07.009","article-title":"Intermittent Administration of Valacyclovir is Effective for Prevention of Herpes Zoster Events in Patients With Multiple Myeloma Treated With Bortezomib","author":"Yao","year":"2014","journal-title":"China Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1201-9712(07)60021-6","article-title":"Prevention of Herpes Zoster and its Painful and Debilitating Complications","volume":"11","author":"Johnson","year":"2007","journal-title":"Int J Infect Dis Ijid Off Publ Int Soc Infect Dis"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.843032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T07:18:02Z","timestamp":1646983082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.843032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":15,"alternative-id":["10.3389\/fonc.2022.843032"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.843032","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"article-number":"843032"}}